COM:HARMONYBIOSCIENCES
Harmony Biosciences
- Stock
Last Close
33.23
22/11 21:00
Market Cap
1.90B
Beta: -
Volume Today
487.85K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | 544K - | 2.46M 351.38% | 4.13M 68.09% | 4.36M 5.74% | 4.83M 10.67% | ||
average payables | 3.91M - | 4.46M 13.99% | 1.78M 60.11% | 2.39M 34.58% | 10.76M 349.47% | ||
average receivables | 2.13M - | 13.22M 521.18% | 28.51M 115.73% | 44.79M 57.11% | 64.44M 43.87% | ||
book value per share | 1.66 - | -0.21 112.66% | 3.77 1,899.21% | 3.24 14.03% | 6.81 110.00% | 7.74 13.62% | |
capex per share | -0.03 - | -2.30 8,339.46% | -0.08 96.62% | -1.74 2,144.28% | -0.68 61.06% | -0.01 99.24% | |
capex to depreciation | -7.29 - | -39.61 443.09% | -0.20 99.51% | -5.32 2,622.20% | -1.72 67.73% | -0.01 99.25% | |
capex to operating cash flow | 0.03 - | 1.69 4,773.07% | 0.67 60.21% | -1.02 251.73% | -0.28 72.68% | -0.00 99.49% | |
capex to revenue | -21.21 - | -0.01 99.94% | -0.33 2,520.12% | -0.09 72.06% | -0.00 99.42% | ||
cash per share | 1.70 - | 0.44 73.92% | 8.87 1,905.09% | 4.07 54.09% | 5.46 34.08% | 5.85 7.22% | |
days of inventory on hand | 251.82 - | 50.31 80.02% | 29.14 42.08% | 18.79 35.52% | 16.15 14.06% | ||
days payables outstanding | 1.47K - | 33.63 97.72% | 6.58 80.43% | 16.55 151.53% | 53.38 222.47% | ||
days sales outstanding | 259.06 - | 50.67 80.44% | 41.64 17.83% | 45.63 9.59% | 46.49 1.89% | ||
debt to assets | 0.92 - | 0.45 50.45% | 0.44 2.62% | 0.28 35.79% | 0.24 16.12% | ||
debt to equity | -8.45 - | 2.00 123.64% | 1.03 48.50% | 0.48 53.78% | 0.41 12.87% | ||
dividend yield | 0.21 - | ||||||
earnings yield | -0.02 - | -0.08 252.86% | -0.06 27.95% | 0.01 125.34% | 0.06 294.65% | 0.07 18.72% | |
enterprise value | 1.74B - | 2.12B 21.88% | 897.29M 57.66% | 2.41B 168.68% | 3.21B 33.08% | 1.83B 42.90% | |
enterprise value over ebitda | -42.15 - | -14.85 64.76% | 64.48 534.16% | 27.54 57.29% | 26.66 3.20% | 7.92 70.29% | |
ev to operating cash flow | -44.82 - | -28.09 37.31% | -300.60 969.96% | 24.46 108.14% | 22.21 9.21% | 8.35 62.40% | |
ev to sales | 353.52 - | 5.62 98.41% | 7.89 40.52% | 7.33 7.17% | 3.15 57.04% | ||
free cash flow per share | -0.82 - | -3.66 349.55% | -0.19 94.72% | -0.03 84.36% | 1.76 5,924.28% | 3.63 105.88% | |
free cash flow yield | -0.02 - | -0.10 349.55% | -0.01 94.59% | -0.00 86.74% | 0.03 4,607.21% | 0.11 251.21% | |
graham net net | 1.54 - | -1.63 205.92% | -3.21 96.93% | 0.27 108.51% | 1.61 489.29% | 1.11 30.78% | |
graham number | 5.49 - | 3.67 33.17% | 13.07 255.83% | 6.62 49.31% | 21.67 227.25% | 19.27 11.08% | |
income quality | 0.97 - | 0.50 48.96% | 0.08 83.72% | 2.85 3,425.73% | 0.80 72.05% | 1.70 113.87% | |
intangibles to total assets | 0 - | 0.68 Infinity% | 0.38 43.81% | 0.33 12.65% | 0.24 28.07% | 0.17 29.26% | |
interest coverage | 0.13 - | 2.87 2,099.17% | 7.67 167.61% | 8.08 5.38% | |||
interest debt per share | 1.77 - | 8.63 387.18% | 3.75 56.52% | 3.50 6.66% | 3.60 2.74% | ||
inventory turnover | 1.45 - | 7.26 400.57% | 12.53 72.65% | 19.43 55.09% | 22.61 16.36% | ||
invested capital | -8.45 - | 2.00 123.64% | 1.03 48.50% | 0.48 53.78% | 0.41 12.87% | ||
market cap | 1.82B - | 2.05B 12.27% | 931.67M 54.46% | 2.45B 163.31% | 3.26B 32.91% | 1.95B 40.19% | |
net current asset value | 78.93M - | -86.79M 209.96% | -67.00M 22.80% | 37.50M 155.97% | 129.25M 244.65% | 106.61M 17.52% | |
net debt to ebitda | 2.02 - | -0.52 125.44% | -2.47 379.75% | -0.48 80.43% | -0.43 10.40% | -0.51 17.87% | |
net income per share | -0.81 - | -2.86 252.86% | -2.01 29.63% | 0.60 129.89% | 3.07 409.97% | 2.13 30.40% | |
operating cash flow per share | -0.79 - | -1.36 73.19% | -0.12 91.51% | 1.71 1,579.08% | 2.44 42.51% | 3.63 48.84% | |
payables turnover | 0.25 - | 10.85 4,276.63% | 55.46 411.08% | 22.05 60.24% | 6.84 68.99% | ||
receivables turnover | 1.41 - | 7.20 411.27% | 8.77 21.70% | 8.00 8.75% | 7.85 1.86% | ||
research and ddevelopement to revenue | 11.61 - | 0.12 98.95% | 0.10 18.34% | 0.16 62.84% | 0.13 19.28% | ||
return on tangible assets | -0.45 - | -4.58 924.62% | -0.20 95.72% | 0.12 161.00% | 0.35 196.07% | 0.19 45.99% | |
revenue per share | 0.11 - | 6.20 5,615.20% | 5.31 14.34% | 7.40 39.38% | 9.64 30.29% | ||
roe | -0.49 - | 13.64 2,887.75% | -0.53 103.91% | 0.19 134.76% | 0.45 142.84% | 0.28 38.75% | |
roic | -0.53 - | -1.76 232.82% | 0.02 101.01% | 0.17 847.19% | 0.35 108.86% | 0.22 38.36% | |
sales general and administrative to revenue | 6.07 - | 0.25 95.90% | 0.21 15.91% | 0.19 8.29% | 0.16 14.68% | ||
shareholders equity per share | 1.66 - | -0.21 112.66% | 3.77 1,899.21% | 3.24 14.03% | 6.81 110.00% | 7.74 13.62% | |
stock based compensation to revenue | 1.65 - | 0.03 98.22% | 0.05 74.50% | 0.06 16.60% | 0.05 8.87% | ||
tangible asset value | 81.53M - | -83.77M 202.75% | -65.16M 22.21% | 42.59M 165.36% | 241.88M 467.97% | 329.88M 36.38% | |
tangible book value per share | 1.66 - | -1.52 191.52% | -2.53 66.85% | 0.74 129.28% | 4.09 452.21% | 5.46 33.67% | |
working capital | 79.45M - | 11.61M 85.39% | 128.35M 1,006.01% | 230.66M 79.71% | 321.40M 39.34% | 287.29M 10.61% |
All numbers in (except ratios and percentages)